Regeneron Entered into a Research Collaboration with CytomX to Develop Conditional Bispecific Therapies for the Treatment of Cancer
Shots:
- CytomX to receive a $30M up front along with future target nomination fees, ~$2B in preclinical, clinical & commercial milestones along with royalties
- The collaboration will use CytomX's Probody therapeutic platform & Regeneron's Veloci-Bi bispecific Ab development platform to develop conditionally-activated bispecific cancer therapies
- Regeneron will fund preclinical, clinical development, & commercialization activities. The collaboration focuses on developing Regeneron bispecifics that remain inactive until activated by proteases in the tumor microenvironment by using CytomX's biologic masking strategies, potentially reducing off-target effects for T-cell engaging therapies & widening their therapeutic window
Ref: Regeneron | Image: Regeneron
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
